CARsgen Therapeutics has received approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to begin CT041's Phase II clinical trial for the treatment of Gastric Cancer Pipeline Drugs Market.
Claudin18.2 (CLDN18.2) is the target of the autologous chimeric antigen receptor (CAR) T-cell product candidate CT041
The trial will look at CT041, a systemic treatment for CLDN18.2-positive advanced GC/GEJ patients who have failed at least two previous treatments.
Dr. Zonghai Li, the founder, chairman of the board, CEO, and chief scientific officer of CARsgen Therapeutics, stated: With the endorsement of CT041 to start the corroborative Stage II clinical preliminary of gastric malignant growth, we are above and beyond to effectively acquire the CT041 showcasing authorisation.
"We believe that CT041 has a great potential to change the paradigm of treatment for advanced gastric cancer worldwide, with our continuous research and development," the company states.
The company mentioned that CT041 focuses on treating solid tumors that are CLDN18.2-positive, particularly GC/GEJ and pancreatic cancer (PC).
CT041 was found to offer favorable therapeutic safety in ongoing trials.
As indicated by CARsgen, CT041 can turn into a spine treatment for GC/GEJ and PC, helping a tremendous patient populace universally.
The company's CT053 was granted RMAT designation by the US Food and Drug Administration in October 2019 for the treatment of relapsed and refractory multiple myeloma (rrMM).
CT053 is a fully human anti-B Cell Maturation Antigen treatment that is an autologous CAR T-cell treatment.
